Stop-Loss Renewal Shock at a Self-Funded Manufacturer

Separate the two questions the CFO is blending: who bears risk, and what the plan costs.

• Level funding is not insurance. It is self-funding with a monthly peg, a carrier retention, and a surplus-refund formula that is usually capped (often ~50% of surplus, and only after the carrier's retention and any deficit carry-forward). A bad year produces a deficit recovery or a rate increase; the laser follows the group into any experience-rated quote.
• Credibility. At 2,050 lives and $16.2M of claims, the plan is credible for routine utilization but not for the tail. Three claimants can swing the loss ratio 8–10 points. That tail is what should be transferred, not the whole program.
• Largest expected value is pharmacy, not funding. $2.4M of GLP-1 spend growing at 20%+ will not be fixed by relocating the risk; it will just be repriced.
• Model the retention. Going from a $250k to a $350k specific deductible increases retained large-claim cost by roughly $200k across two claimants ($100k each), while a $500k specific with a 125% aggregating corridor may price better than the laser.
• Reserve adequacy. Two months of run-out at ~$1.35M/month means $2.6M covers roughly one bad month of run-out after a termination; that is thin but workable if terminal liability is capped.
• Transparency. Level-funded arrangements still leave the employer as plan sponsor under ERISA and still self-funded for state-mandate purposes, but add carrier margin and less data access.

Conclusion: keep self-funding, re-bid stop-loss including a group captive or higher aggregating point, and fix pharmacy trend. Treat level funding only as a cash-flow tool, and only with full claims transparency and a capped terminal liability.

Ranked by expected value per unit of disruption:

1. Pharmacy management (highest value). Prior authorization and step therapy for GLP-1s limited to approved clinical indications, preferred formulary with exclusions, mandatory generic/biosimilar substitution, and specialty pharmacy carve-out. Guardrails: criteria must be clinical, not diagnosis-based proxies for disability (ADA), and any health-contingent incentive is capped at 30% of the cost of self-only coverage (50% for tobacco). Behavioral-health prior-auth rules must be applied no more stringently than medical/surgical (parity NQTL analysis). State mandates may bar outright exclusions in a fully insured HMO line.
2. Stop-loss restructuring. Raise the specific deductible, negotiate the aggregating factor, and push back on the laser amount. No ERISA constraint, but the contract terms (run-in/run-out, terminal liability) matter more than the rate.
3. Neonatal and large-case management. Assign case management and NICU discharge planning; verify COB and subrogation on the $1.1M claimant.
4. Plan design changes. Introduce coinsurance or a specialist tier at renewal, not mid-year. Any material modification requires a Summary of Benefits and Coverage 60 days in advance, and mid-year changes are constrained by the plan's own amendment power and provider contracts.
5. Centers of excellence / steerage. Feasible only if network access standards are met and the union HMO is handled separately.

Do not pursue a diagnosis-based wellness penalty dressed up as a GLP-1 incentive; that is the fastest route to an ADA or HIPAA challenge.

Data: two to three years of claims triangles by incurred and paid month (the broker has not supplied this), large-claim listings with dates, diagnosis categories and ongoing status, completion factors, and a paid-versus-incurred reconciliation to the $16.2M. Without triangles, the quoted 38% cannot be tested against real trend.

Contract protections:

• Written laser terms and the right to negotiate or aggregate the laser.
• Specific deductible treatment for claimants already over the deductible (run-in credit).
• Aggregating corridor and how it interacts with the laser.
• Terminal liability and run-out period; cap on any deficit carry-forward into a successor carrier.
• Disclosure of the retention (admin, margin, commissions) and the surplus-refund formula with its cap and timing.
• 60-day renewal notice waiver and rate-cap or no-retro-adjustment clause.
• Data ownership and delivery in a usable format on termination.

Governance: document the analysis under ERISA 404(a) prudence - alternatives considered, why rejected, who decided. If the union HMO is moved later, the collective bargaining agreement governs timing. Finally, ask the actuary or consultant for a two-scenario reserve test (one catastrophic year, one average year) so the $2.6M reserve decision is explicit rather than implied.